OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more OSE Immunotherapeutics Charts. Click Here for more OSE Immunotherapeutics Charts.](/p.php?pid=staticchart&s=EU%5EOSE&p=8&t=15)
Iconix Announces Chemogenomics Collaborative Relationship with
AstraZeneca
MOUNTAIN VIEW, Calif., June 2 /PRNewswire/ -- Iconix Pharmaceuticals, Inc.
today announced that AstraZeneca has selected Iconix to provide advanced
chemogenomic profiling and analytical services for a specific AstraZeneca
Cancer drug discovery program, using Iconix's reference database and predictive
biomarkers.
Under the agreement, AstraZeneca will apply Iconix's chemogenomics platform to
developing an understanding of the mechanisms of toxicity found in specific
drug programs. AstraZeneca is also seeking to identify genomic biomarkers that
can be used as counterscreens in short-term studies. These biomarkers would be
designed to predict the onset of specific toxicologies and would facilitate the
development of follow-up compounds and, potentially, drug response monitoring
in clinical testing.
Iconix will utilize biomarkers of drug pathology and mechanism from its Drug
Signatures(TM) library, the largest collection of predictive biomarkers in the
pharmaceutical industry, for the profiling of AstraZeneca's compounds. Drug
Signatures are derived by Iconix from its DrugMatrix(R) platform, a large-scale
chemogenomics reference database and informatics system.
"We're especially pleased to be working with AstraZeneca," said Jim Neal,
Iconix's CEO, "because the work focuses on two areas of chemogenomics
technology that can provide great benefits -- predictive toxicology and
understanding the mechanisms of toxicology. Reducing the time to detecting
potential toxicity and developing an understanding of those toxicities can
significantly reduce the cost of drug development in the clinic."
About Iconix:
Iconix Pharmaceuticals, Inc. is pioneering the new field of chemogenomics, the
integration of chemistry and genomics to profile drug candidates. Iconix's
chemogenomic capabilities enable pharmaceutical companies to increase the odds
of advancing the right compounds to the clinic, reducing attrition rates and
the costs of drug discovery. Iconix provides reference systems and know-how to
predict toxic liabilities, side effects and mechanisms of drug candidates. The
company has strategic partnerships with an ecosystem of leading life sciences
companies, including MDS Pharma Services (NYSE:MDZ)(TSE:MDS), Incyte
Corporation (NASDAQ:INCY) and Amersham Biosciences (NYSE:AHM) ( LSE: OSE) , and
collaborations with Bristol Myers Squibb, Abbott Laboratories, Eli Lilly,
Schering-Plough, Eisai Co., Ltd. and Millennium Pharmaceuticals, Inc. Iconix
also provides research, training and support to the U.S. Food and Drug
Administration, Center for Drug Evaluation and Research (CDER) under an
agreement to advance CDER's study of the application of genomic technologies in
the regulatory approval process. Iconix's DrugMatrix system has been installed
at the FDA for use by CDER scientists and reviewers in a diverse range of
chemogenomics applications. Headquartered in Mountain View, California, Iconix
was founded in 1998 and is privately held. For more information, visit
http://www.iconixpharm.com/.
About AstraZeneca:
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one of the
world's leading pharmaceutical companies with healthcare sales of over $18.8
billion and leading positions in sales of gastrointestinal, oncology,
cardiovascular, neuroscience and respiratory products. AstraZeneca is listed
in the Dow Jones Sustainability Index (Global and European) as well as the
FTSE4Good Index. Worldwide, AstraZeneca has six major research and development
sites, four discovery facilities and a clinical research site, in total,
employing more than 11,500 R&D staff members in Canada, France, India, Japan,
Sweden, United Kingdom and the United States.
CONTACT:
For Iconix Pharmaceuticals
Jennifer Larson
415-409-2729
DATASOURCE: Iconix Pharmaceuticals, Inc.
CONTACT: Jennifer Larson, +1-415-409-2729, or , for
Iconix Pharmaceuticals, Inc.
Web site: http://www.iconixpharm.com/